HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Medicare Part D Formulary Placement: Bundled Up, Or Out In The Cold?

Executive Summary

Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies
Advertisement

Related Content

Part D 2007 Negotiations: Will Rebate Emphasis Change To Pricing Demands?
Pfizer Medicare Part D Negotiations Not Focusing On Dual-Eligible Plans
Welcome To Medicare: Pfizer Sees Part D As Key To Rebirth
Merck Sales Restructuring Sacrifices Physician Detailing To Payer Marketing
Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?
Lipitor Is Medicare Rx Marketing Tool For Drug Plans, Pfizer Says
Lipitor Is Medicare Rx Marketing Tool For Drug Plans, Pfizer Says
Schering Negotiating 150 Drug Contracts With Part D Plans
PBMs Looking Beyond Traditional Rebate Model In Selling Medicare Part D
“Lifestyle” Drug Coverage Will Be Federal Policy Issue Under Medicare Rx
Advertisement
UsernamePublicRestriction

Register

PS046718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel